| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5658972 | Gastroenterology | 2016 | 44 Pages |
Abstract
Regimens containing ledipasvir and sofosbuvir are highly effective for a broad spectrum of patients with HCV genotype 1 infection treated in different clinical practice settings. Expanded use of 8-week treatment regimens for eligible patients is supported by these real-world results. Modification of proton pump inhibitor use may increase rates of SVR. ClinicalTrials.gov no. NCT01474811.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Gastroenterology
Authors
Norah A. Terrault, Stefan Zeuzem, Adrian M. Di Bisceglie, Joseph K. Lim, Paul J. Pockros, Lynn M. Frazier, Alexander Kuo, Anna S. Lok, Mitchell L. Shiffman, Ziv Ben Ari, Lucy Akushevich, Monika Vainorius, Mark S. Sulkowski, Michael W. Fried,